Glooko Targets Health-System Scale With EndoTool and Integrated Diabetes Data Strategy

Glooko is sharpening its focus on hospital and health system customers, using its EndoTool inpatient glycemic management platform to build an integrated diabetes data ecosystem. The company is aligning its strategy with the American Diabetes Association’s 2026 Standards of Care, which call for closer linkage of inpatient and outpatient data.

Recent communications highlight EndoTool IV’s performance across Advocate Health’s 19-hospital network, where it reportedly delivered a 98% reduction in severe hypoglycemia versus paper protocols. The data, presented at the 2026 American Association of Clinical Endocrinology Annual Meeting, underscore Glooko’s push to demonstrate system-level safety and scalability.

Glooko is also emphasizing interoperability between its outpatient diabetes data platforms and EndoTool in the hospital setting, framing the combined offering as an “actionable ecosystem” for glycemic control. By targeting large health systems and enterprise deployments, the company aims to embed its software more deeply in clinical workflows and support recurring revenue streams.

The company’s sponsorship of the 2026 Mid-Atlantic Patient Safety Conference further signals its bid to position EndoTool as a differentiated clinical decision support tool for inpatient diabetes care. This visibility with hospital decision-makers could help expand its provider network, although no new contracts or financial metrics were disclosed.

If Glooko can replicate the reported clinical outcomes across additional health systems and integrate smoothly with hospital IT infrastructure, it may strengthen its competitive position in both inpatient and outpatient diabetes management. Overall, the week’s developments point to a strategy centered on standards-driven interoperability, health-system scale, and clinically validated safety benefits.